Teclistamab Reviewed as Potential Treatment Option in Relapsed/Refractory Multiple Myeloma
CancerNetwork hosted a Training Academy focused on sequencing therapies for patients with multiple myeloma who are treated with bispecific antibodies.
August 2023 Snap Recap: Chemo Shortages, FDA Approvals in Multiple Myeloma
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Artificial Intelligence May Improve Detection, Prostate Cancer Decision Making
Across several clinical trials, Unfold AI appears to help in prostate cancer treatment selection and follow-up.
FDA Updates Temozolomide Prescribing Information in Brain Cancer
Prescribing information has been updated to include temozolomide as adjuvant treatment for adult patients with newly diagnosed anaplastic astrocytoma or refractory anaplastic astrocytoma.
Adagrasib Shows Enduring Activity in KRAS G12C+ Non–Small Cell Lung Cancer
Treatment with adagrasib appears to be particularly well tolerated in patients with KRAS G12C–mutated non–small cell lung cancer who receive it for more than 1 year.
FDA Grants FTD to Tulmimetostat in Advanced ARID1A+ Endometrial Cancer
Data from a phase 1/2 trial support the fast track designation for tulmimetostat as a treatment for patients with ARID1A-mutated advanced, recurrent or metastatic endometrial cancer.
Iruplinalkib Elicits Significant PFS in ALK+ Advanced/Metastatic NSCLC
Iruplinalib appears tolerable with no new safety signals among patients with locally advanced and metastatic ALK-positive non–small cell lung cancer in the phase 3 INSPIRE trial.
Drug Price Negotiations: One Long-Overdue “Small Step” for the American Health Care Consumer
Co-editor-in-chief, Howard S. Hochster, MD, reviews the ongoing drug price negotiations and the effect it will have in the health care space.
Sacituzumab Govitecan Combo Yields Early Activity in Metastatic NSCLC
Data from the phase 2 EVOKE-02 trial support further assessment of sacituzumab govitecan plus pembrolizumab as a frontline treatment for metastatic non–small cell lung cancer.
Neoadjuvant Chemo/Surgery Appears Non-Superior to CRT in Cervical Cancer
Investigators report acceptable morbidity and health-related quality of life with neoadjuvant chemotherapy plus surgery and concomitant chemoradiotherapy in those with cervical cancer.
Stem Cell Transplant Yields Enduring Disease Control in TP53-Mutated MCL
Allogeneic stem cell transplant should be strongly considered as a treatment for patients with mantle cell lymphoma who are adequately fit, according to Thomas E. Lew.
Benmelstobart Combo Improves PFS and OS Vs Placebo in Extensive-Stage SCLC
Benmelstobart plus anlotinib and chemotherapy produce survival benefits in extensive-stage small cell lung cancer across all patient subgroups in the phase 3 ETER701 trial.
Osimertinib/Chemo Elicits Meaningful PFS in EGFR+ NSCLC
Investigators report a progression-free survival benefit with osimertinib plus chemotherapy in EGFR-mutated non–small cell lung cancer across all subgroups in the phase 3 FLAURA2 study.
FDA Grants FTD to AFM13/AB-101 in Relapsed/Refractory Hodgkin Lymphoma
Investigators will assess AFM13 in combination with AB-101 as a treatment for those with relapsed or refractory Hodgkin lymphoma in the phase 2 LuminICE-203 trial.
Data Suggest Worse Survival in Black Low-Risk Endometrial Cancer Population
Findings suggest the presence of different genetic pathways that may drive disparities in outcomes between Black and White patients with endometrioid endometrial cancer, according to Kristin Taylor, MD.
Flow Cytometry/Cytomorphological Features Correlate with MDS Prognosis
Characteristics including Ogata score and phenotypic aberrancies may correlate with mutational patterns that are predictive of treatment response in patients with myelodysplastic syndrome.
EMA Accepts Application for Erdafitinib in EGFR+ Urothelial Carcinoma
Findings from the phase 3 THOR study support the marketing authorization application for erdafitinib as a treatment for those with advanced or metastatic urothelial cancer harboring FGFR3 alterations.
Loncastuximab Tesirine Combo Shows Promising Activity, Safety in DLBCL
Treatment with loncastuximab tesirine-lpyl in the safety run-in portion of the LOTIS-5 study appears to be promising, according to Michal Kwiatek, MD, PhD
Motixafortide/Filgrastim OKed by FDA for Transplantation in Multiple Myeloma
A single dose of motixafortide results in achievement of stem cell collection goal in patients with multiple myeloma.
Many Factors Influence Selection of CAR T Therapy, Bispecifics in Myeloma
Bispecific antibodies may be more broadly applicable as treatment for patients with multiple myeloma in the short-term, according to Ajai Chari, MD.
Treatment Goals and Disease Risks May Inform Treatment Selection in CML
Asciminib may be more tolerable than bosutinib in the treatment of those with chronic myeloid leukemia, according to Michael Deininger, MD.
ctDNA May Play Role in Large Cell Lymphoma Detection
Data from previous studies demonstrate that pretreatment levels of circulating tumor DNA may be prognostic in diffuse large B-cell lymphoma, according to Mark J. Roschewski, MD.
Cilta-Cel Yields PFS, Durable Responses in R/R Multiple Myeloma
Patients with multiple myeloma and enduring MRD-negativity are able to achieve the deepest responses with ciltacabtagene autoleucel, according to Yi Lin, MD, PhD.
Nelarabine and Daratumumab Produce Promising Outcomes in T-ALL Trials
It may be an optimal approach to improve first-line treatment options to prevent relapse in those with T-cell acute lymphoblastic leukemia, according to Kristen O’Dwyer, MD.
Intensive Vs Non-Intensive Chemo Yields Similar Outcomes in Elderly AML
Investigators report no differences in rates of graft-versus-host-disease with intensive or non-intensive consolidation chemotherapy prior to transplantation for elderly patients with acute myeloid leukemia.
Molecular Responses with Ponatinib Correlate with PFS/OS Outcomes in CML
A major molecular response at 3 months appears to increase the probability of overall survival in patients treated with ponatinib for chronic-phase chronic myeloid leukemia in the phase 2 PACE trial.
Luspatercept Controls Anemia in Transfusion Dependent MDS Population
Luspatercept may provide clinical benefit regardless of subgroup and baseline mutation burden in transfusion dependent patients with myelodysplastic syndrome with anemia, according to Guillermo Garcia-Manero, MD.
Ponatinib/Chemotherapy Elicits MRD-Negative Remissions in Ph+ ALL
Ponatinib also produces an improvement in progression-free survival compared with imatinib among those with Philadelphia chromosome-positive acute lymphoblastic leukemia in the phase 3 PhALLCON trial.
Pediatric-Based Treatment Warrants Future Study in ALL Subtype
Investigators report a higher recurrence-free survival rate for patients receiving a pediatric-inspired protocol regimen compared with an adult chemotherapy regimen in a retrospective review.
Socio-Racial Factors May Impact Primary Myelofibrosis Outcomes
Mohammad Bakri Hammami, MD, highlights a need to address socio-racial disparities among Black and non-Black patients with primary myelofibrosis to ensure that everyone receives high-quality treatment.
